Phase I study of GC1008 (fresolimumab): a human anti‐transforming growth factor‐beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In advanced cancers, transforming growth factor-beta (TGFβ) promotes tumor growth and metastases and suppresses host antitumor immunity. GC1008 is a human anti-TGFβ monoclonal antibody that neutralizes all isoforms of TGFβ. Here, the safety and activity of GC1008 was evaluated in patients with advanced malignant melanoma and renal cell carcinoma. METHODS: In this multi-center phase I trial, cohorts of patients with previously treated malignant melanoma or renal cell carcinoma received intravenous GC1008 at 0.1, 0.3, 1, 3, 10, or 15 mg/kg on days 0, 28, 42, and 56. Patients achieving at least stable disease were eligible to receive Extended Treatment consisting of 4 doses of GC1008 every 2 weeks for up to 2 additional courses. Pharmacokinetic and exploratory biomarker assessments were performed. RESULTS: Twenty-nine patients, 28 with malignant melanoma and 1 with renal cell carcinoma, were enrolled and treated, 22 in the dose-escalation part and 7 in a safety cohort expansion. No dose-limiting toxicity was observed, and the maximum dose, 15 mg/kg, was determined to be safe. The development of reversible cutaneous keratoacanthomas/squamous-cell carcinomas (4 patients) and hyperkeratosis was the major adverse event observed. One malignant melanoma patient achieved a partial response, and six had stable disease with a median progression-free survival of 24 weeks for these 7 patients (range, 16.4-44.4 weeks). CONCLUSIONS: GC1008 had no dose-limiting toxicity up to 15 mg/kg. In patients with advanced malignant melanoma and renal cell carcinoma, multiple doses of GC1008 demonstrated acceptable safety and preliminary evidence of antitumor activity, warranting further studies of single agent and combination treatments. TRIAL REGISTRATION: Clinicaltrials.gov NCT00356460.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Fresolimumab, a human monoclonal antibody against TGF‐β in a phase 1 clinical trial (NCT00356460), demonstrated preliminary evidence of anti‐tumor activity in malignant melanoma and renal cell carcinoma [42].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 4×
“Recently, targeted therapies directed against B-RAF and other genes have been used successfully to treat patients with MM [33].”
BackgroundInfluentialMassagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
Tumor Self-Seeding by Circulating Cancer Cells
Kim, M.-Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H.-F., Norton, L., & Massagué, J. (2009) · Cell · doi:10.1016/j.cell.2009.11.025 · Cited by 1,335 · cited 1×
“Norton and Massague [48,49] have proposed that cancer cell migration and ‘‘re-seeding’’ of the primary tumor with cells primed for metastatic growth leads to a tumor with heterogenous subpopulations of aggressive, rapidly growing cancer cells that may become resistant to treatment.”
BackgroundRAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Su, F., Viros, A., Milagre, C., Trunzer, K., Bollag, G., Spleiss, O., Reis-Filho, J. S., Kong, X., Koya, R. C., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105358 · Cited by 1,038
TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4
Padua, D., Zhang, X. H.-F., Wang, Q., Nadal, C., Gerald, W. L., Gomis, R. R., & Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.01.046 · Cited by 952
Roberts, A. B., Anzano, M. A., Lamb, L. C., Smith, J. M., & Sporn, M. B. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5339 · Cited by 919 · cited 1×
“Transforming growth factor-beta (TGFb) is a pleiotropic cytokine that is a member of a superfamily of ligands that includes bone morphogenetic proteins and activins [1,2].”
BackgroundKorn, E. L., Liu, P.-Y., Lee, S. J., Chapman, J.-A. W., Niedzwiecki, D., Suman, V. J., Moon, J., Sondak, V. K., Atkins, M. B., Eisenhauer, E. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7837 · Cited by 705
Terabe, M., Matsui, S., Park, J.-M., Mamura, M., Noben-Trauth, N., Donaldson, D. D., Chen, W., Wahl, S. M., Ledbetter, S., Pratt, B., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022227 · Cited by 539
Self-citationTransforming Growth Factor-β and the Immune Response: Implications for Anticancer Therapy
Wrzesinski, S. H., Wan, Y. Y., & Flavell, R. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1157 · Cited by 452 · cited 2×
“With broad activity in natural killer (NK) cells, T cells including T regulatory cells, NKT cells, monocytes/ macrophages, and dendritic cells, TGFb can down-regulate both primary and secondary immune responses and suppress antitumor effector cells [3,11,12].”
Background
Cited by
Items 201–300 of 508
The role of innate lymphoid cells in health and disease
Mohammadi, H., Sharafkandi, N., Hemmatzadeh, M., Azizi, G., Karimi, M. H., Jadidi‐Niaragh, F., Baradaran, B., & Babaloo, Z. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26250 · Cited by 44
“Additionally, keratinocyte-derived TSLP can also activate ILC2s without impressing by IL-13 and IL-4 (Kinoshita et al., 2009; Morris et al., 2014).”
BackgroundInfluentialTransforming growth factor-β signaling: from tumor microenvironment to anticancer therapy
Chan, M. K., Chan, E. L.-Y., Ji, Z. Z., Chan, A. S. W., Li, C., Leung, K. T., To, K., & Tang, P. M. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00137 · Cited by 45
“Type Treatment Mechanism Status Reference Antibodies Fresolimumab Neutralization of TGF-β1, TGF-β2 and TGF-β3 Phase II [124]”
BackgroundWang, L., Xie, L., Tintani, F., Xie, H., Li, C., Cui, Z., Wan, M., Zu, X., Qi, L., & Cao, X. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0411 · Cited by 41
Frangogiannis, N. G. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2316735 · Cited by 42
“In metastatic melanoma patients, treatment with the anti-TGF-β antibody fresolimumab was associated with rashes and with reversible nonmalignant keratoacanthomas, without any evidence of cardiovascular toxicity [116].”
BackgroundCytokines frequently implicated in myeloproliferative neoplasms
Wang, Y., & Zuo, X. (2019) · Cytokine X · doi:10.1016/j.cytox.2019.100005 · Cited by 46
Li, O., Li, L., Sheng, Y., Ke, K., Wu, J., Mou, Y., Liu, M., & Jin, W. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216391 · Cited by 46
Targeting transforming growth factor beta signaling in metastatic osteosarcoma
Ge, R., & Huang, G. M. (2023) · Journal of bone oncology · doi:10.1016/j.jbo.2023.100513 · Cited by 40
“The development of reversible cutaneous keratoacanthomas/squamous-cell carcinomas and hyperkeratosis were the major adverse events observed [122].”
BackgroundChang, S., Lv, J., Wang, X., Su, J., Bian, C., Zheng, Z., Yu, H., Bao, J., Xin, Y., & Jiang, X. M. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104461 · Cited by 41
New therapies for hepatic fibrosis
Koyama, Y., & Brenner, D. A. (2015) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2015.06.011 · Cited by 37
Mellone, M., Piotrowska, K., Venturi, G., James, L., Bzura, A., Lopez, M. A., James, S., Wang, C., Ellis, M. J., Hanley, C. J., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0435 · Cited by 39
“Inhibiting TGFb, however, can be problematic; this pleiotropic cytokine has multiple roles in normal physiology as well as tumor-suppressive effects, and its targeting has led to ontarget cardiac toxicities in preclinical studies, as well as the development of cutaneous tumors in human trials (18, 55).”
BackgroundNatural killer cell receptors: alterations and therapeutic targeting in malignancies
Konjević, G. M., Vuletić, A. M., & Martinović, K. M. (2015) · Immunologic Research · doi:10.1007/s12026-015-8695-4 · Cited by 40
“In order to diminish tumor-induced immunosuppression, early-stage clinical trials have been introduced using anti-TGF-b monoclonal antibodies such as fresolimumab, a fully humanized pan-neutralizing antibody directed against all the three isoforms of TGF-b, that have been assessed in renal cell carcinoma and metastati…”
Chemoradiation induces epithelial‐to‐mesenchymal transition in esophageal adenocarcinoma
Steins, A., Ebbing, E. A., Creemers, A., van der Zalm, A. P., Jibodh, R. A., Waasdorp, C., Meijer, S. L., van Delden, O. M., Krishnadath, K. K., Hulshof, M. C. C. M., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32364 · Cited by 38
Extracellular matrix in skin diseases: The road to new therapies
Malta, M. D., Cerqueira, M. T., & Marques, A. P. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.11.008 · Cited by 35
Relevance and consequence of chronic inflammation for obesity development
Rück, L., Wiegand, S., & Kühnen, P. (2023) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-023-00170-6 · Cited by 35
Nana, A. W., Yang, P.-M., & Lin, H. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.16.6813 · Cited by 39
“This antitumor property led to its clinical translation in several cancers including GBM, malignant melanoma and renal cell carcinoma attesting to its safety and potential therapeutic effect (Morris et al., 2014).”
BackgroundTGF-β-Based Therapies for Treating Ocular Surface Disorders
Ogata, F. T., Verma, S., Coulson‐Thomas, V. J., & Gesteira, T. F. (2024) · Cells · doi:10.3390/cells13131105 · Cited by 36
He, X., Han, S., Li, X.-H., Zheng, W., Pang, L., Jiang, S., & Li, P. (2017) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2017.04.008 · Cited by 35
Paton‐Hough, J., Tazzyman, S. J., Evans, H., Lath, D., Down, J. M., Green, A. C., Snowden, J. A., Chantry, A., & Lawson, M. A. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3606 · Cited by 40
The extracellular matrix in inflammation and cancer
Zhang, W., Xiang, Y., Lu, C., Wang, F., Ren, H., Wu, H., & Yan, M. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00415-6 · Cited by 38
Current Advance of Therapeutic Agents in Clinical Trials Potentially Targeting Tumor Plasticity
Yang, X., Zhu, L.-C., Wang, Y., Li, Y., & Wang, D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00887 · Cited by 35
The Role of the Transforming Growth Factor-β Signaling Pathway in Gastrointestinal Cancers
Matsuoka, T., & Yashiro, M. (2023) · Biomolecules · doi:10.3390/biom13101551 · Cited by 36
“…was unsatisfactory because of their systemic efficacy on normal tissues of TGF-β , which causes undesirable side effects such as fatigue, gingival bleeding, headache, epistaxis, and TGF-β -related skin lesions, including reversible cutaneous keratoacanthomas/squamous-cell carcinomas [179,180].”
BackgroundBeyond checkpoint inhibition – Immunotherapeutical strategies in combination with radiation
Eckert, F., Gaipl, U. S., Niedermann, G., Hettich, M., Schilbach, K., Huber, S. M., & Zips, D. (2017) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2016.12.006 · Cited by 33
“Other strategies include toll-like receptor agonists [16], TGFb blockade [17], NK cell based therapy [18] and immune”
BackgroundAhuja, S., & Zaheer, S. (2023) · Cell Biology International · doi:10.1002/cbin.12097 · Cited by 37
“GC1008 (fresolimumab), a monoclonal antibody that is pan ‐ specific is seen to bind to all the isoforms of TGF ‐ β and decrease their aberrant activities during tumor progression (Morris et al., 2014).”
BackgroundInfluentialLorenzo, G. D., Placido, S. D., Pagliuca, M., Ferro, M., Lucarelli, G. T., Rossetti, S., Bosso, D., Puglia, L., Pignataro, P., Ascione, I., et al. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1216964 · Cited by 33
“Further studies of single agent and combination treatments are required [97].”
BackgroundExploring the potential of TGFβ as a diagnostic marker and therapeutic target against cancer
Garg, P. K., Pareek, S., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116646 · Cited by 35
Clinical translation of immunomodulatory therapeutics
Nash, A., Aghlara-Fotovat, S., Hernández, A., Scull, C. M., & Veiseh, O. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113896 · Cited by 32
Microvascular significance of TGF-β axis activation in COVID-19
Arguinchona, L., Zagona‐Prizio, C., Joyce, M. E., Chan, E. D., & Maloney, J. P. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1054690 · Cited by 41
Phytochemicals as Immunomodulatory Agents in Melanoma
Tabolacci, C., Vita, D. D., Facchiano, A., Bozzuto, G., Beninati, S., Failla, C. M., Martile, M. D., Lintas, C., Mischiati, C., Stringaro, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032657 · Cited by 30
Yim, L. Y., Lam, K. S., Luk, T., Mo, Y., Lu, X., Wang, J., Cheung, K., Lui, G. C.-Y., Chan, D. P. C., Wong, B. C. K., et al. (2023) · Journal of Virology · doi:10.1128/jvi.00270-23 · Cited by 30
Qayoom, H., Alkhanani, M., Almilaibary, A., Alsagaby, S. A., & Mir, M. A. (2023) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2023.103705 · Cited by 32
“Numerous clinical trials conducted in recent years have established the effectiveness of TGF-b targeted medications in treating a range of tumor and fibrotic illnesses (Mehraj et al., Declèves and Sharma 2014, Morris et al., 2014, Herbertz et al., 2015).”
BackgroundFlynn, M. J., & Larkin, J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1369956 · Cited by 30
“of clinical antitumor activity [101] providing the rationale for”
BackgroundYang, Y., Yang, H. H., Tang, B., Wu, A. M. L., Flanders, K. C., Moshkovich, N., Weinberg, D. S., Welsh, M. A., Weng, J., Ochoa, H. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2370 · Cited by 29
Comprehensive Review of Osteogenesis Imperfecta: Current Treatments and Future Innovations
Chaugule, S. R., Constantinou, C. K., John, A. A., Micha, D., Eekhoff, E. M. W., Gravallese, E. M., Gao, G., & Shim, J. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.191 · Cited by 30
Cutaneous Squamous Cell Carcinoma in the Age of Immunotherapy
Ishitsuka, Y., Hanaoka, Y., Tanemura, A., & Fujimoto, M. (2021) · Cancers · doi:10.3390/cancers13051148 · Cited by 29
“Likewise, LOF mutations in TGFBR1 cause self-healing cSCC-like lesions that resemble KAs in Ferguson–Smith disease (FSD) [90], similarly as the pan-TGFβ–blocking antibody fresolimumab (GC1008) [91,92].”
BackgroundKhasraw, M., Weller, M., Lorente, D., Kolibaba, K. S., Lee, C. K., Gedye, C. A., de la Fuente, M. I., Vicente, D., Reardon, D. A., Gan, H. K., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab058 · Cited by 43
Sohn, M.-H., Kim, S. I., Shin, J.-Y., Kim, H. S., Chung, H. H., Kim, J., Lee, M., & Seo, J. (2021) · Genes · doi:10.3390/genes12071103 · Cited by 33
Kodet, O., Dvořánková, B., ⁄, B. B., ⁄, V. S. ⁄. K., ⁄, I. K., Štork, J., Kučera, J., Szabó, P., Strnad, H., ř, M. K. ⁄., et al. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3448 · Cited by 31
TGF-beta signaling in cancer: post-transcriptional regulation of EMT via hnRNP E1
Howley, B. V., & Howe, P. H. (2018) · Cytokine · doi:10.1016/j.cyto.2017.12.032 · Cited by 32
He, J. N., Gao, Y., Jing, L., Yang, H., & Liu, S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1489701 · Cited by 33
Orrapin, S., Thongkumkoon, P., Udomruk, S., Moonmuang, S., Sutthitthasakul, S., Yongpitakwattana, P., Pruksakorn, D., & Chaiyawat, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512337 · Cited by 28
Corneal fibrosis: From in vitro models to current and upcoming drug and gene medicines
Cubillo, L. T., Gürdal, M., & Zeugolis, D. I. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115317 · Cited by 33
Antibody-Based Immunotherapy of Solid Cancers: Progress and Possibilities
Nicodemus, C. F. (2015) · Immunotherapy · doi:10.2217/imt.15.57 · Cited by 32
Sarhan, D., Leijonhufvud, C., Murray, S. M., Witt, K., Seitz, C., Wallerius, M., Xie, H., Ullén, A., Harmenberg, U., Lidbrink, E. K., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1338238 · Cited by 28
“Results indicated increased infiltration of CD8C T cells in the invasive margin, however the correlation between Treg- TGFb and CD8C T cell infiltration was not examined.(38) Other strategies to deplete circulating Treg were made by e.”
BackgroundWelsh, B. T., Faucette, R., Bilic, S., Martin, C. J., Schürpf, T., Chen, D. J., Nicholls, S. B., Lansita, J. A., & Kalra, A. V. (2021) · International Journal of Toxicology · doi:10.1177/1091581821998945 · Cited by 28
Pancreatic Cancer: Pathogenesis and Clinical Studies
Zhou, K., Liu, Y., Tang, C., & Zhu, H. (2025) · MedComm · doi:10.1002/mco2.70162 · Cited by 35
Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?
Passiglia, F., Reale, M. L., Cetoretta, V., & Novello, S. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s253581 · Cited by 30
Advances in Immunotherapy and the TGF-β Resistance Pathway in Metastatic Bladder Cancer
Benjamin, D. J., & Lyou, Y. (2021) · Cancers · doi:10.3390/cancers13225724 · Cited by 30
“Fresolimumab is a human anti-TGF-β Ig 4k monoclonal antibody that acts on all three TGF-β isoforms, including TGF-β1, TGF-β2, and TGF-β3 [91].”
BackgroundInfluentialTGF-β in tumor development and progression: mechanisms and therapeutics
Liu, J., Wang, Y., Tang, C., Zhang, L., Xiong, S., Wang, J., & Dong, C. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00403-w · Cited by 31
“Early pan-TGF-β inhibitors (e.g., Fresolimumab and Galunisertib), which concomitantly block all TGF-β isoforms, disrupt vascular homeostasis and platelet function, thus leading to severe adverse effects such as hemorrhage and cardiotoxicity [247, 249, 312].”
InfluentialVugmeyster, Y., Grišić, A., Wilkins, J. J., Loos, A. H., Hallwachs, R., Osada, M., Venkatakrishnan, K., & Khandelwal, A. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04468-6 · Cited by 27
Huang, Q., Liu, M.-C., Zhang, D., Lin, B.-B., Fu, X., Zhang, Z., Zhang, B., & Dong, J. (2023) · BMC Medicine · doi:10.1186/s12916-023-02763-4 · Cited by 28
Ganaie, A. A., Mansini, A. P., Hussain, T., Rao, A., Siddique, H. R., Shabaneh, A., Ferrari, M. G., Murugan, P. J., Klingelhöfer, J., Wang, J., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0410 · Cited by 25
Zhang, Y., Ding, X., Zhang, X., Li, Y., Xu, R. C., Li, H., Zuo, D., & Chen, G. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1404687 · Cited by 33
Approaches for targeting cancer stem cells drug resistance
Rosa, R., D’Amato, V., Placido, S. D., & Bianco, R. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1243525 · Cited by 28
“Different inhibitors of this pathway are being investigated in clinic [97].”
BackgroundHourani, T., Sharma, A., Luwor, R. B., & Achuthan, A. A. (2024) · International Reviews of Immunology · doi:10.1080/08830185.2024.2411998 · Cited by 28
Targeting inflammatory microenvironments: overcoming therapy resistance and immunosuppression
Zhou, Y., Bai, M., Chen, L., Han, H., Hou, S., Wang, X., Fan, P., Han, S., Chen, F., Li, J., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02583-z · Cited by 33
Small extracellular vesicle TGF-β in cancer progression and immune evasion
Hosseini, R., Hosseinzadeh, N., Asef‐Kabiri, L., Akbari, A., Ghezelbash, B., Sarvnaz, H., & Akbari, M. E. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00638-7 · Cited by 28
“Antibodies like Fresolimumab [122], LY3022859 [123] as well as soluble TGF-β RII/RIII [124, 125] can block TGF-β - receptor binding and prevent its adverse effects.”
BackgroundNavigating the Cytokine Seas: Targeting Cytokine Signaling Pathways in Cancer Therapy
Stanilov, N., Velikova, T. V., & Stanilova, S. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021009 · Cited by 29
“Neutralizing monoclonal IgG antibodies against both TGF-β (fresolimumab) and TGFBRII (LY3022859) have demonstrated a significant decrease in tumor growth and metastasis in animal models and phase-II clinical trials [87,88].”
BackgroundCanè, S., Snick, J. V., Uyttenhove, C., Pilotte, L., & den Eynde, B. J. V. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001798 · Cited by 27
Harnessing Natural Killer Cells in Cancer Immunotherapy: A Review of Mechanisms and Novel Therapies
St‐Pierre, F., Bhatia, S., & Chandra, S. (2021) · Cancers · doi:10.3390/cancers13081988 · Cited by 25
“Fresolimumab is a TGF-β neutralizing monoclonal antibody that has shown good tolerability in a phase I trial with patients with advanced melanoma and renal cell carcinoma, as well as preliminary evidence of antitumor activity [89].”
BackgroundEffect of preoperative chemoradiotherapy on the immunological status of rectal cancer patients
Yasui, K., Kondou, R., Iizuka, A., Miyata, H., Tanaka, E., Ashizawa, T., Nagashima, T., Ohshima, K., Urakami, K., Kusuhara, M., et al. (2020) · Journal of Radiation Research · doi:10.1093/jrr/rraa041 · Cited by 24
The emerging promise of tumour mechanobiology in cancer treatment
Papavassiliou, K. A., Basdra, E. K., & Papavassiliou, A. G. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.112938 · Cited by 25
Radiotherapy in the age of cancer immunology: Current concepts and future developments
Loi, M., Desideri, I., Greto, D., Mangoni, M., Sottili, M., Meattini, I., Becherini, C., Terziani, F., Paoli, C. D., Olmetto, E., et al. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.002 · Cited by 25
Kato, S., Berzofsky, J. A., & Terabe, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00314 · Cited by 26
“In humans, an antibody that neutralizes all three isoforms of active TGF-β has shown clinical benefit in some patients with metastatic malignant melanoma (98, 99).”
BackgroundSelf-citationKreps, L. M., & Addison, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062911 · Cited by 26
Kodama, S., Podyma‐Inoue, K. A., Uchihashi, T., Kurioka, K., Takahashi, H., Sugauchi, A., Takahashi, K., Inubushi, T., Kogo, M., Tanaka, S., et al. (2021) · Oncology Reports · doi:10.3892/or.2021.8148 · Cited by 22
“…melanomas, there have also been attempts to target TGF‑ β signals by using antisense oligonucleotides (trabedersen; API12009) (23), monoclonal anti‑TGF‑ β anti‑ bodies (fresolimumab; GC1008) (24) or a low molecular weight compound (vactosertib; TEW‑7197) that inhibits T β RI kinase activity (25).”
Leveraging cellular mechano-responsiveness for cancer therapy
Hyun, J., & Kim, H. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.11.006 · Cited by 23
Guo, Y., Wang, Z., Zhou, H., Pan, H., Han, W., Deng, Y., Li, Q., Xue, J., Ge, X., Wang, S., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12216-7 · Cited by 22
“However, it is frequently observed in mAbs and ligand traps targeting this pathway [16, 17].”
BackgroundBuenrostro, D., Kwakwa, K. A., Putnam, N. E., Merkel, A. R., Johnson, J., Cassat, J. E., & Sterling, J. A. R. (2018) · Bone · doi:10.1016/j.bone.2018.05.008 · Cited by 23
“TGF-β inhibitors are currently in clinical trials for the treatment of gliomas, metastatic breast cancer, non-small cell lung cancer, melanoma, mesothelioma and renal cell carcinoma (52-54).”
BackgroundNext-Generation Immunotherapies to Improve Anticancer Immunity
Shi, Y., Tomczak, K. J., Li, J., Ochieng, J. K., Lee, Y., & Haymaker, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.566401 · Cited by 24
“The therapeutic approach currently tested in clinical trials includes targeting TGFβ signaling using specific antibodies or through molecules targeting its receptors (Morris et al., 2014; Herbertz et al., 2015).”
MethodGonzàlez-Juncà, A., Reiners, O., Borrero-García, L. D., Beckford-Vera, D., Lazar, A., Chou, W. S., Braunstein, S. E., VanBrocklin, H. F., Franc, B. L., & Barcellos‐Hoff, M. H. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.09.043 · Cited by 24
Becker, W., Olkhanud, P. B., Seishima, N., Moreno, P. A., Goldfarbmuren, K. C., Maeng, H. M., & Berzofsky, J. A. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008970 · Cited by 23
Self-citationChallenges and Opportunities in Targeting the Complex Pancreatic Tumor Microenvironment
Finan, J. M., Guo, Y., Goodyear, S. M., & Brody, J. R. (2024) · JCO oncology advances. · doi:10.1200/oa-24-00050 · Cited by 23
“55 56-58 Inhibiting TGF-b signaling partially attenuates tumor cell growth by altering CAF and immune cell dynamics 59-62 ; however, the complexity of inhibiting TGF-b signaling is re fl ected by unsuccessful trials and discontinued development of several drug candidates (Table 1).”
Cho, Y. A., Kim, E., Cho, B. C., Koh, Y. W., & Yoon, S. O. (2019) · Anticancer Research · doi:10.21873/anticanres.13841 · Cited by 21
Strategies to boost antibody selectivity in oncology
Blay, V., & Pandiella, A. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.10.005 · Cited by 23
The role of macrophages in asthma-related fibrosis and remodelling
Yang, X., Li, F., Zhang, G., Foster, P. S., & Yang, M. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108820 · Cited by 23
Shifting Shapes: The Endothelial-to-Mesenchymal Transition as a Driver for Cancer Progression
Giordanengo, L., Proment, A., Botta, V., Picca, F., Munir, H., Tao, J., Olivero, M., Taulli, R., Bersani, F., Sangiolo, D., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136353 · Cited by 20
Mirea, M. A., Eckensperger, S., Hengstschläger, M., & Mikula, M. (2020) · Cancers · doi:10.3390/cancers12092508 · Cited by 23
Molecular Pathways and Mechanisms of TGFβ in Cancer Therapy
Barcellos‐Hoff, M. H., & Gulley, J. L. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3750 · Cited by 21
Bone marrow microenvironment in cancer patients: immunological aspects and clinical implications
Stefanovic, S., Schütz, F., Sohn, C., Beckhove, P., & Domschke, C. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9397-1 · Cited by 21
Scherer, S. D., Bauer, J., Schmaus, A., Neumaier, C., Herskind, C., Veldwijk, M. R., Wenz, F. K., & Sleeman, J. P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162221 · Cited by 22
“Fresolimumab (GC1008), a panTGF-β neutralizing antibody has been used in clinical trials to treat patients with a variety of malignancies and with different forms of fibrosis [70].”
BackgroundInhibition of the V-ATPase by Archazolid A: A New Strategy to Inhibit EMT
Merk, H., Messer, P. K., Ardelt, M. A., Lamb, D. C., Zahler, S., Müller, R., Vollmar, A. M., & Pachmayr, J. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0129 · Cited by 21
Banerjee, A., & Singh, J. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10150 · Cited by 26
Vugmeyster, Y., Wilkins, J. J., Köenig, A., Bawab, S. E., Dussault, I., Ojalvo, L. S., Banerjee, S. D., Klopp‐Schulze, L., & Khandelwal, A. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1776 · Cited by 20
TGFβ Signaling in the Tumor Microenvironment
Goulet, C. R., & Pouliot, F. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-47189-7_6 · Cited by 22
Goudie, D. R. (2020) · Genes · doi:10.3390/genes11121410 · Cited by 20
“In a phase 1 study using GC1008 (Fresolimumab), a human anti-TGFβ monoclonal antibody, to treat advanced malignant melanoma or renal cell carcinoma, 4 out of 29 patients developed keratoacanthoma or squamous cell carcinoma-like skin tumors [43].”
BackgroundThe Complexities of TGF-β Action During Mammary and Squamous Cell Carcinogenesis
Connolly, E. C., & Akhurst, R. J. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111798808284 · Cited by 21
Immunocytokines and cytokine neutralization for cancer immunotherapy
Berraondo, P., Cuesta, R., Aranda, F., Riaño, A. M., Eguren‐Santamaría, I., Luri‐Rey, C., Risson, A., Melero, A., Gomis, G., & Melero, I. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.04.014 · Cited by 24
Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy
Cao, J., Zhang, Z., Zhou, L., Luo, M., Li, L., Li, B., Nice, E. C., He, W., Zheng, S., & Huang, C. (2023) · MedComm · doi:10.1002/mco2.427 · Cited by 22
New insights into fibrotic signaling in renal cell carcinoma
Chen, J., Yiu, W. H., Tang, P. M., & Tang, S. C. W. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1056964 · Cited by 19
“Early in 2014, a phase I clinical study used the human TGF-β1/β2/β3 neutralizer GC1008 (fresolimumab) to treat patients with advanced malignant melanoma and RCC (Morris et al., 2014).”
BackgroundStructure, unique biological properties, and mechanisms of action of transforming growth factor β
Zelisko, N., Lesyk, R., & Стойка, Р. С. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107611 · Cited by 19
Effect of cancer-associated fibroblasts on radiosensitivity of cancer cells
Ji, X., Zhu, X., & Lu, X. (2017) · Future Oncology · doi:10.2217/fon-2017-0054 · Cited by 19
Loss of TGF-β signaling drives cSCC from skin stem cells – More evidence
Rose, A., Sansom, O. J., & Inman, G. J. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1259892 · Cited by 18
“Convincing reports include the genotypephenotype correlation between inactivating TGFBR1 mutation and familial multiple self-healing squamous epithelioma (MSSE),(4) as well as reports of spontaneous cSCC arising secondary to systemic treatment with the pan-TGF-b ligand antibody (GC1008).(5) In addition, TGF-b receptor…”
BackgroundNeutrophils in cancer: At the crucial crossroads of anti‐tumor and pro‐tumor
Cai, W., Fan, T. T., Xiao, C., Deng, Z., Liu, Y., Li, C., & He, J. (2025) · 癌症:英文版 · doi:10.1002/cac2.70027 · Cited by 23
“Fresolimumab, an antibody capable of neutralizing all human isoforms of TGF-β , has shown an acceptable safety profile and preliminary evidence of anti-tumor activity in various cancer patients in phase I/II trials [266, 267].”
Investigating the Role of TGF-β Signaling Pathways in Human Corneal Endothelial Cell Primary Culture
Aouimeur, I., Sagnial, T., Coulomb, L., Maurin, C., Thomas, J., Forestier, P., Ninotta, S., Perrache, C., Forest, F., Gain, P., et al. (2023) · Cells · doi:10.3390/cells12121624 · Cited by 16
Innate lymphoid cells are pivotal actors in allergic, inflammatory and autoimmune diseases
Sanati, G., Aryan, Z., Barbadi, M., & Rezaei, N. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.1050382 · Cited by 19
“ILC2s act as pivotal actors in pathogenesis of allergic diseases Asthma For several years, pathogenesis of allergic diseases was attributed to the essential role of adaptive Th2 cells by producing IL-4, informahealthcare.com 887 IL-5 and IL-13, collectively named type 2 cytokines [20].”
BackgroundInfluentialWu, X., Xiao, Y., Guo, D. H., Zhang, Z., & Liu, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.849493 · Cited by 17
Berzofsky, J. A. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.11.034 · Cited by 17
Self-citationOkpasuo, O. J., Olaoba, O. T., Bokolo, P., Aleke, A. S., Dare, A., Adelusi, T. I., & Jackson, C. D. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105037 · Cited by 18
GPCRs and fibroblast heterogeneity in fibroblast‐associated diseases
Dwivedi, N. V., Datta, S., El‐Kersh, K., Sadikot, R. T., Ganti, A. K., Batra, S. K., & Jain, M. (2023) · The FASEB Journal · doi:10.1096/fj.202301091 · Cited by 17
Novel biological strategies to enhance the radiation therapeutic ratio
Kim, J. H., Jenrow, K. A., & Brown, S. L. (2018) · Radiation Oncology Journal · doi:10.3857/roj.2018.00332 · Cited by 17
“Using an anti-TGFβ monoclonal antibody, phase I clinical trials were carried out in patients with advanced malignant melanoma and renal cell carcinoma [61].”
Method
Metadata
- Authors
- Morris, J. C., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Reiss, M., Hsu, F. J., Berzofsky, J. A., & Lawrence, D. P.
- Affiliations
- National Cancer Institute (US)
- Rutgers Cancer Institute (US)
- The Ohio State University (US)
- Dana-Farber Cancer Institute (US)
- Beth Israel Deaconess Medical Center (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Morris, John C.
- Berzofsky, Jay A.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-03-11
- Volume
- 9
- Issue
- 3
- Pages
- e90353
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3949712
- OpenAlex
- W2075873658
- Cited by
- 487
- References
- 50
- Citations by year
- 2026: 29 · 2025: 39 · 2024: 48 · 2023: 47 · 2022: 36 · 2021: 46 · 2020: 49 · 2019: 30 · 2018: 29 · 2017: 41 · 2016: 30 · 2015: 29 · 2014: 9
- FWCI
- 14.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Massachusetts General Hospital
- Ohio State University
- Rutgers Cancer Institute of New Jersey
- National Institutes of Health
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- TGF-beta, melanoma, renal cell carcinoma, advanced cancer, dose escalation, safety, pharmacokinetics, keratoacanthoma, squamous cell carcinoma, anticancer activity, progression-free survival
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Melanoma, Middle Aged, Neoplasm Staging, Tomography, X-Ray Computed, Transforming Growth Factor beta, Treatment Outcome, Positron-Emission Tomography, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.